In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology.
This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from the pioneering work of Jokichi Takamine and the early days of enzyme therapeutics, to the merger that unified biological extraction with synthetic chemistry, and ultimately to the company’s bold, high-stakes bet on antibody-drug conjugates (ADCs).
At the center of it all is Enhertu, the drug that shattered the traditional HER2 classification and redefined how we think about targeting cancer. We unpack how Daiichi Sankyo solved the ADC “linker problem,” engineered a platform with unmatched precision, and built a pipeline that’s now reshaping treatment across breast, lung, and gastric cancers.
We also explore the strategic partnerships with AstraZeneca and Merck & Co., and what they signal about Daiichi Sankyo’s position as a true platform leader in the ADC gold rush.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #DaiichiSankyo #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Enhertu #LifeSciences #BiotechPodcast #PetriDishPerspectives
© 2026 The Perspective Bureau LLC. All rights reserved.
